Beta Bionics (NASDAQ:BBNX) CFO Sells $108,059.58 in Stock

Key Points

• Beta Bionics CFO Stephen Feider sold 4,982 shares of the stock for approximately $108,059, reducing his ownership by 10.16%.
• Beta Bionics stock is currently trading at $22.15, up 0.9%, and the company has a 52-week range between $8.89 and $26.66.
• Analysts have issued varied ratings on Beta Bionics, with one rating it as a Strong Buy and others suggesting a price target range of $17 to $30.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 4,982 shares of Beta Bionics stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $21.69, for a total transaction of $108,059.58. Following the sale, the chief financial officer owned 44,041 shares of the company's stock, valued at approximately $955,249.29. The trade was a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Stephen Feider also recently made the following trade(s):

• On Wednesday, October 1st, Stephen Feider sold 15,018 shares of Beta Bionics stock. The shares were sold at an average price of $20.76, for a total transaction of $311,773.68.
• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The stock was sold at an average price of $21.00, for a total value of $2,100.00.
• On Tuesday, September 2nd, Stephen Feider sold 1,462 shares of Beta Bionics stock. The stock was sold at an average price of $18.86, for a total value of $27,573.32.
• On Friday, August 22nd, Stephen Feider sold 4,413 shares of Beta Bionics stock. The stock was sold at an average price of $17.01, for a total value of $75,065.13.
• On Tuesday, August 19th, Stephen Feider sold 5,587 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total value of $95,146.61.

Beta Bionics Trading Up 0.9%

Shares of Beta Bionics stock traded up $0.20 during trading on Tuesday, hitting $22.15. 278,651 shares of the company were exchanged, compared to its average volume of 597,707. Beta Bionics, Inc. has a fifty-two week low of $8.89 and a fifty-two week high of $26.66. The firm has a 50 day moving average price of $19.37 and a 200 day moving average price of $15.83.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.12. The company had revenue of $23.24 million for the quarter, compared to analysts' expectations of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BBNX. Lake Street Capital initiated coverage on shares of Beta Bionics in a report on Thursday, June 12th. They issued a "buy" rating and a $30.00 price objective on the stock. Weiss Ratings restated a "sell (d)" rating on shares of Beta Bionics in a research note on Saturday, September 27th. Robert W. Baird set a $17.00 target price on shares of Beta Bionics and gave the company a "neutral" rating in a research note on Wednesday, July 30th. Truist Financial upped their target price on shares of Beta Bionics from $21.00 to $28.00 and gave the company a "buy" rating in a research note on Monday, September 22nd. Finally, The Goldman Sachs Group set a $26.00 target price on shares of Beta Bionics and gave the company a "buy" rating in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $24.44.

Institutional Trading of Beta Bionics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio acquired a new stake in Beta Bionics during the first quarter valued at approximately $29,000. Legal & General Group Plc lifted its stake in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company's stock valued at $58,000 after purchasing an additional 2,639 shares during the last quarter. CWM LLC purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $58,000. Corebridge Financial Inc. purchased a new stake in shares of Beta Bionics in the 1st quarter valued at approximately $79,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Beta Bionics in the 1st quarter valued at approximately $95,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.